We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Global Market for Women’s Health Devices Sees Moderate Growth

By HospiMedica International staff writers
Posted on 29 Nov 2015
The global market for women’s health devices is forecast to grow from an estimated USD 1.8 billion in 2014 to approximately USD 2.4 billion in 2021, representing a compound annual growth rate of 3.7%. These are the latest findings of GlobalData (London, United Kingdom), an international business intelligence provider.

The market encompasses treatments for conditions that are particular to the adult female anatomy; this includes abnormal uterine conditions, such as menorrhagia and uterine fibroids, pelvic disorders such as female stress urinary incontinence, and anti-conceptive procedures. Minimally invasive technologies to treat these conditions as alternatives to conventional surgery are expected to see increased adoption in the coming years, due to increased physician and patient awareness and an increasing number of women proactively seeking treatment.

Technologies include endometrial resection devices, uterine fibroid embolization agents, female sterilization devices, and female urinary incontinence slings. As more women seek treatment for uterine health and incontinence issues, the market will become increasingly competitive, provided that the new technology meets efficacy and safety standards. However, recent lawsuits related to safety issues with some of these devices have received widespread media attention, particularly in the urinary incontinence sling market, causing some skepticism.

“The understanding that a woman’s quality of life can be vastly improved by new technologies coincides with the awareness that a variety of new treatment options, such as global endometrial ablation and uterine artery embolization, are far less invasive than surgery,” said GlobalData analyst Premdharan Meyyan. “For women who suffer from abnormal uterine conditions, such as heavy menstrual bleeding and uterine fibroids, these new technologies offer safe and effective alternative treatment options to patients who do not wish to undergo invasive surgery.”

Related Links:

GlobalData



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
X-ray Diagnostic System
FDX Visionary-A
New
Mini C-arm Imaging System
Fluoroscan InSight FD

Latest Business News

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024

Boston Scientific to Acquire AFib Ablation Company Cortex